In 2022, MJFF and the ASAP Initiative formed a working group to discuss improving robustness and reproducibility of the alpha-synuclein pre-formed fibril model. The workshop was divided into three section to cover (1) characterizing the protein injectate, (2) understanding the model and interpreting phenotypes, and (3) choosing between recombinant protein, brain homogenate, and amplified patient material as injectate. This document contains the discussion summary.